Investors

ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense^® line of products to protect newborn calves against scours (neonatal calf diarrhea), a leading cause of death that the Company estimates costs U.S. industry up to $1 billion per year. First Defense^® is USDA-licensed franchise of scours prevention products and a stable revenue and profit growth driver.

Recent News

Corporate Presentation

Recent Quarterly Filing

Q1 2026 Form 10Q

2026 Meeting of Stockholders

Thursday, June 11, 2026, beginning at 9:30 AM ET

Proxy Statement

You are invited to attend the annual meeting of stockholders of ImmuCell Corporation Annual Meeting. The meeting will be held on Thursday June 11, 2026 at 9:30AM, ET. The annual meeting will be a completely ‘‘virtual meeting’’ of stockholders. You will be able to attend the annual meeting as well as submit your questions during the live webcast of the meeting by visiting  www.virtualshareholdermeeting.com/ICCC2026  and entering the 16‐digit control number included in our notice of Internet availability of the proxy materials, on your proxy card or in the instructions that accompanied your proxy materials.

For those who prefer to connect by phone, please use the following dial in instructions:

PARTICIPANT DIAL IN NUMBER:                        1-877-328-2502                           
PARTICIPANT INTERNATIONAL DIAL IN:         1-412-317-5419           
 
When greeted by the operator, please request the ImmuCell Corporation Annual Meeting.  Your 16-digit control number will be required. Participants will then be placed on hold until the meeting begins. 

Conference Calls